| |
BIOMARKERS, IMAGING AND SAFETY IN RESMETIROM 52-WEEK
NON-CIRRHOTIC NASH PHASE 3 CLINICAL TRIAL, COMPLETED
OPEN-LABEL ARM OF MAESTRO-NAFLD-1
|
| |
| |
AASLD Nov 2021
Dr. Stephen A. Harrison, Radcliffe Department of Medicine, University of Oxford; Ms. Sarah Cubberly, Duke University; Dr. Rebecca A. Taub, Madrigal Pharmaceuticals; Dr. Guy W. Neff, Covenant Research and Clinics, LLC; Dr. Naim Alkhouri, Arizona Liver Health; Dr. Mustafa Bashir, Duke University
| |
| |
| |
|
|
|
